13F Holdings
中文EN

ENSC Ensysce Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1716947 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY37.9%
TTM net income YoY-729.4%
TTM EPS YoY-18.3%
Revenue 3-yr CAGR25.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,477.0%
Net margin-1,470.4%
FCF margin—
EBITDA margin-1,476.6%

Returns

ROE-635.4%
ROA-533.3%
ROIC (approx.)—
Asset turnover0.36x

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.02x
Interest coverage-7,157.58x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-484.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$5.07M$5.21M$2.23M$2.52M$3.53M
R&D expense$10.38M$7.22M$7.59M$19.84M$4.69M
SG&A expense$4.93M$4.72M$5.36M$6.91M$18.71M
Operating income-$10.24M-$6.73M-$10.72M-$24.22M-$19.87M
Interest expense$18,767$1.29M$353,945$109,525$1.30M
Net income-$10.18M-$7.99M-$10.61M-$24.17M-$29.08M
EBITDA-$10.23M-$6.73M-$10.72M-$24.22M-$19.87M
EPS (basic)-3.98-11.45-70.40-139.42-29.64
EPS (diluted)-3.98-11.45-70.40-139.42-1.48
Weighted avg. shares (diluted)2.56M697,686150,937179,92520.16M
Banking
Provision for credit losses——-$150-$3-$1,808
Balance sheet
Cash & equivalents$4.31M$3.50M$1.12M$3.15M$12.26M
Current assets$7.25M$5.34M$2.29M$5.30M$15.66M
PP&E, net$124,129————
Total assets$7.45M$5.60M$2.71M$5.89M$16.42M
Current liabilities$4.57M$2.21M$3.33M$9.46M$16.48M
Total liabilities$4.57M$2.22M$3.36M$9.91M$24.58M
Shareholders' equity$3.21M$3.71M-$322,858-$3.71M-$7.88M
Shares outstanding4.57M1.36M209,739534,4901.23M
Cash flow statement
Operating cash flow-$7.81M-$7.50M-$10.78M-$17.89M-$8.24M
Capital expenditure$123,643————
Free cash flow-$7.93M————
Investing cash flow-$123,643——$4,500—
Financing cash flow$8.74M$9.88M$8.76M$8.77M$20.31M
Depreciation & amortization$6,533$0$0$0$151
Stock-based compensation$177,086$110,723$879,160$1.07M$121,764

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.